Glioblastoma and other gliomas — a hard, immunosuppressed CNS setting where neoantigen vaccines are being tested as early intervention.
Washington University School of Medicine is running a Phase I study of a personalized neoantigen-based DNA vaccine combined with retifanlimab (PD-1 blockade) in newly diagnosed, unmethylated glioblastoma. The trial assesses safety and immunogenicity, targeting a population with limited therapeutic options.
Beijing Tiantan Hospital completed a Phase I study evaluating autologous dendritic cells loaded with tumor neoantigen peptides alongside temozolomide in newly diagnosed glioblastoma. The trial focused on safety and preliminary efficacy, contributing data on DC-based vaccine platforms in this indication.
CancerNetwork reports that a personalized cancer vaccine combined with pembrolizumab is feasible and effective in patients with newly diagnosed glioblastoma (GBM). This supports the strategy of pairing neoantigen vaccines with PD-1 blockade in aggressive CNS tumors.
Washington University School of Medicine is assessing a personalized neoantigen-based DNA vaccine in newly diagnosed, unmethylated glioblastoma. This trial targets a difficult-to-treat brain cancer subtype, testing the feasibility and immunogenicity of DNA-based delivery in the CNS.
Dana-Farber Cancer Institute is running a Phase 1 trial of a personalized neoantigen cancer vaccine combined with radiation therapy and pembrolizumab for newly diagnosed glioblastoma. The study aims to determine the safety and appropriate dosing of the vaccine, leveraging patient-specific tumor mutations to generate a targeted immunotherapeutic intervention.
Jonsson Comprehensive Cancer Center is running a Phase I trial for a neoantigen-targeted peptide-pulsed dendritic cell (ppDC) vaccine in patients with H3 G34-mutant diffuse hemispheric glioma. The active, non-recruiting study focuses on identifying the best dose and safety profile of this patient-specific immunotherapy.
ZSky Biotech Inc is conducting a multicenter, randomized Phase II study of ZSNeo-DC1.1, a personalized dendritic cell vaccine, combined with temozolomide for newly diagnosed glioblastoma. The trial’s primary endpoint is progression-free survival (PFS) per RANO 2.0 criteria, with exploratory objectives assessing antigen-specific T-cell responses.
Docwire News reports that a personalized neoantigen vaccine has generated immune activity and encouraging survival signals in glioblastoma (GBM). This signal reinforces the clinical viability of personalized approaches in aggressive CNS tumors, though specific sponsor or trial phase details are not provided in the summary.
A Phase 1 trial published in Nature investigates adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma. The study explores the feasibility and immunogenicity of DNA-based platforms in the context of standard adjuvant therapy for this aggressive brain cancer.